A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients

Trial Profile

A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms CERKI
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Oct 2013 Planned End Date changed from 1 Feb 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 13 Nov 2012 Actual initiation date changed from 1 Feb 2012 to Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top